Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

SciClone Pays $20 Million to AbilityPharma for China Rights to Cancer Drug

publication date: May 12, 2016
SciClone, a US pharma focused on the China market, in-licensed China rights to a solid tumor cancer drug from Spain's AbilityPharma in a deal potentially worth $20 million. ABTL0812 has completed a Phase I/Ib trial in Spain. In exchange for greater China rights to the drug, SciClone will make an upfront payment along with development, regulatory and sales milestones plus royalties. In Europe and the US, ABTL081 was given Organ Drug status for pediatric cancer neuroblastoma. More details....

Stock Symbol: (NSDQ: SCLN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China